Anthera Shares Plunge on Stopping Heart Trial for Lack of Effectiveness
Anthera declined to $3.56 at the close of trading, for the biggest single-day drop since the Hayward, California-based company first sold shares to the public in March 2010.
Anthera closed enrollment in the study and told investigators to immediately remove patients from the therapy, varespladib, the company said in a statement on March 9. The treatment was being used with cholesterol-lowering drugs to prevent a recurrence in patients who had suffered from acute coronary syndrome, Anthera said on its website. Varespladib was in the third and final stage of clinical testing generally needed for regulatory approval.
“This new information was totally unexpected and disappointing given the potential benefits of this drug,” Stephen Nicholls, chairman of the executive committee overseeing the trial, said in the statement.
With varespladib’s failure, the company’s lead drug is now blisibimod, a therapy for systemic lupus in the second stage of testing that will face a challenging market, Steve Scala, an analyst at Cowen & Co. in Boston said today in a note to clients.
“A poorly defined lupus market and disappointing sales of novel agents in this space further temper our enthusiasm,” he wrote.
To contact the editor responsible for this story: Reg Gale at firstname.lastname@example.org